查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1458418

伤口治疗生物製品市场评估：依产品、伤口、最终用户和地区划分的机会和预测（2017-2031）

Wound Care Biologics Market Assessment, By Product, By Wound, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 225 Pages | 商品交期: 3-5个工作天内

价格

全球伤口护理生物製剂市场规模将从 2023 年的 20.1 亿美元成长到 2031 年的 33.1 亿美元，预计在 2024-2031 年期间复合年增长率为 6.45%。

糖尿病足溃疡和烧伤增加：

该市场的成长主要是由于烧伤和糖尿病足溃疡盛行率的上升而推动的。随着世界各地糖尿病盛行率的增加，糖尿病足溃疡是一种越来越常见的併发症。每年，美国有 160 万人，全世界有 1,860 万人患有糖尿病足溃疡。约 1% 的糖尿病患者会截肢，5% 的患者会出现足部溃疡。近年来，据估计每年有 1-4% 的糖尿病患者出现足部溃疡。烧伤是一个公共卫生问题，因为烧伤每年导致全球 18 万人死亡。其中近三分之二的病例发生在非洲和中东，其中大多数发生在低收入和中等收入国家。皮肤替代品和生长因子等先进治疗方法是伤口护理生物製剂的一部分，由于它们能够促进癒合和减少併发症，因此变得越来越受欢迎。由于人们认识的提高以及对创新和高效伤口护理解决方案的需求不断增长，伤口治疗生物製剂被认为是解决烧伤和糖尿病足溃疡相关问题的关键。

交通事故增加：

全球道路事故率不断上升，这是推动该市场成长的关键因素之一。对伤口治疗生物製剂的需求是由对快速有效的伤口癒合的不断增长的需求以及对生物製剂治疗的临床益处的日益瞭解所推动的。生长因子和组织工程产品等先进疗法对于加速癒合过程和减少创伤后併发症的可能性至关重要。据估计，每年有 119 万人死于交通事故。交通事故是 5 至 29 岁儿童和年轻人死亡的主要原因。低收入和中等收入国家占世界道路交通死亡人数的 92%。

科技的发展：

伤口护理生物製剂的技术进步正在彻底改变伤口护理领域。这种创新方法利用生长因子、干细胞和细胞激素来刺激组织再生并加速癒合过程。利用组织工程和 3D 列印技术的生物皮肤替代品提供了传统移植物的卓越替代品，提供了更好的贴合性和功能性。外用製剂受益于奈米技术和缓释製剂，提高了其在感染控制和伤口癒合方面的有效性。

北美主导全球伤口护理生物製剂市场：

北美在全球伤口护理生物製剂市场上占据主导地位的原因有很多。该地区拥有完善的医疗基础设施，可以轻鬆引进和整合先进的医疗技术。此外，糖尿病和血管疾病等慢性病的高盛行率增加了对先进伤口护理解决方案的需求，使生物製剂成为治疗方案的重要组成部分。美国和加拿大的监管环境和报销政策进一步促进了创新伤口治疗生物製剂的采用。

该报告调查了全球伤口治疗生物製剂市场，并提供了市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、行业结构、影响市场成长的因素分析、我们编製了案例研究、竞争格局、概况各大公司等等。

目录

第一章研究方法论

第二章 专案范围与定义

第三章执行摘要

第四章 全球伤口治疗生物製剂市场展望

  • 市场规模/预测
  • 依产品
    • 生物皮肤替代品
    • 外用剂
  • 依伤
    • 溃疡
    • 手术伤口与创伤
    • 烧伤
  • 依最终用户
    • 医院/诊所
    • 门诊手术中心
    • 烧伤治疗中心/伤口诊所
  • 依地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美洲
    • 中东/非洲
  • 依公司划分的市场占有率

第五章全球伤口治疗生物製品市场展望：依地区

  • 北美
  • 欧洲
  • 亚太地区
  • 南美洲
  • 中东/非洲

第 6 章 市场测绘

  • 依产品
  • 依伤
  • 依最终用户
  • 依地区

第七章 宏观环境与产业结构

  • 供需分析
  • 进出口分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第八章市场动态

  • 增长动力
  • 成长限制因素（课题与限制）

第九章 监理架构与创新

  • 专利情况
  • 监管审批
  • 创新/新兴技术

第十章 主要公司情况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 名市场领导者的市场收入分析
  • 併购/合资（如适用）
  • SWOT分析（5家参与企业）
  • 专利分析（如果适用）

第11章价格分析

第十二章案例研究

第十三章 主要公司展望

  • Smith & Nephew Plc
  • Integra LifeSciences Corporation
  • Stryker Corporation
  • Organogenesis Inc
  • MixMedx Inc
  • Kerecis Limited
  • Molnlycke Healthcare AB
  • Lynch Biologics
  • Skye Biologics Holdings LLC
  • Marine Polymer Technologies Inc

第十四章 战略建议

第十五章关于我们公司/免责声明

Product Code: MX11215

The global wound care biologics market is projected to witness a CAGR of 6.45% during the forecast period 2017-2031, growing from USD 2.01 billion in 2023 to USD 3.31 billion in 2031F. The global wound care biologics market consists of innovative treatments derived from natural sources or synthetic materials that are utilized in wound care procedures. These biologics include skin replacement products and stem cell therapies, which are essential for promoting tissue regeneration and wound healing. Bioengineered dermal substitutes and other biologic skin substitutes promote neovascularization and collagen formation, among other mechanisms that aid in the healing of chronic ulcers. To treat chronic wounds or diabetic foot ulcers with past histories and increased bioburden, topical agents derived from living organisms or cells are being used more often. Since biologic scaffolds form hydrogels that promote collagen synthesis and wound healing, their use in treating chronic non-healing wounds has shown effective results.

Wound care biologics are widely used in the management and treatment of burns, traumatic injuries, and foot ulcers. Anti-infective wound care products have demonstrated effectiveness in treating wounds with infection, such as diabetic foot ulcers. For long-standing foot ulcers or chronic wounds, biologic interventions have been clinically effective. The global wound care biologics market is being driven significantly by the increasing prevalence of burn injuries, traumatic wounds, and foot ulcers. Other factors that are driving the market growth are technological advancements, a growing geriatric population, and an increasing number of road accidents.

For instance, Biologics company Tides Medical announced the launch of a new product in July 2022, Artacent AC, a tri-layer skin graft designed for use in the treatment of complex or difficult-to-treat wounds. Artacent AC is three times stronger and two times thicker than traditional dual-layer products, making it easier to handle and apply to wound sites. To provide physicians with an advanced amniotic skin graft option, Tides developed Artacent AC, which consists of three layers (amnion-chorion-amnion) as opposed to the conventional two (amnion-amnion).

Increasing Prevalence of Diabetic Foot Ulcer and Burn Injuries

The global wound care biologics market is being driven largely due to the rising incidence of burn injuries and diabetic foot ulcers. Diabetic foot ulcers are among the associated complications that are becoming more common as the prevalence of diabetes increases globally. Every year, 1.6 million Americans and 18.6 million people worldwide suffer from diabetic foot ulcers. About 1% of diabetic patients have their feet amputated, and 5% of patients develop foot ulcers. Over the past few years, it has been estimated that 1-4% of diabetic patients develop foot ulcers each year. Burns are a public health concern since they are responsible for 180,000 deaths globally each year. Almost two-thirds of these are found in the African and South-East Asian regions, with the majority occurring in low- and middle-income countries. Advanced therapies such as skin substitutes and growth factors, which are a part of wound care biologics, are becoming more and more popular for their ability to boost healing and reduce complications. As a result of this increased awareness and the growing need for innovative and efficient wound care solutions, the market for wound care biologics has been positioned as essential to solving the problems associated with burn injuries and diabetic foot ulcers.

Growing Number of Road Accidents

Global traffic accident rates are rising, which is one of the key factors propelling the global wound care biologics market growth. Road accidents frequently cause a range of injuries, from small cuts to severe wounds, necessitating the use of cutting-edge wound care techniques. Demand for wound care biologics is being driven by the growing need for quick and efficient wound healing as well as a greater understanding of the clinical benefits of biologic-based treatments. Advanced therapies, such as growth factors and tissue-engineered products, are essential for accelerating the healing process and reducing the likelihood of complications following traumatic injuries. An estimated 1.19 million people lose their lives in traffic-related incidents each year. For kids and young adults aged 5 to 29, traffic accidents are the main cause of death. Despite having about 60% of the world's vehicles, low- and middle-income countries account for 92% of all road fatalities worldwide.

Technological Advancements

Technological advancements in the global wound care biologics market are revolutionizing the landscape of wound care management. Innovative approaches involve the utilization of growth factors, stem cells, and cytokines to stimulate tissue regeneration and accelerate the healing process. Biological skin substitutes, leveraging tissue engineering and 3D printing technologies, are providing better alternatives to traditional grafts, offering improved compatibility and functionality. Topical agents are benefiting from nanotechnology and sustained release formulations, improving their efficacy in infection control and wound healing.

For instance, in January 2023, Kerecis introduced its GraftGuide fish-skin product line, which addresses the difficulties associated with burn healing. GraftGuide Mano is made to adapt to the shape of a hand. Surgeons do not need to customize the graft because the product can easily cover the three-dimensional structure of the hand. This reduces the surgical time and eliminates the need for numerous grafts and bulky fixation.

Dominance of Hospitals

Due to the complex nature of the hospital environment, wound care is mostly used in hospitals as compared to ambulatory surgical centers and burn care centers. Wounds of varying degrees of severity are more common in hospitals because they typically handle a wide variety of medical cases, including complicated surgeries, trauma, and chronic conditions. Hospitals are equipped with a comprehensive infrastructure that facilitates access to a wide range of wound care resources, advanced diagnostic tools, and specialized medical professionals. Hospitals are the main hub for comprehensive wound care management because they are equipped to handle acute cases that may need intensive care and continuous monitoring. This allows medical professionals to address a wide range of wounds, from severe injuries to post-surgical incisions.

North America Dominates the Global Wound Care Biologics Market

North America's dominance in the global wound care biologics market is being driven by various factors. The region has a well-established healthcare infrastructure that readily adopts and integrates advanced medical technologies. In addition, a high prevalence of chronic conditions such as diabetes and vascular diseases, has led to an increased demand for advanced wound care solutions, positioning biologics as a critical component for treatment protocols. The regulatory environment and reimbursement policies in the United States and Canada further facilitate the widespread adoption of innovative wound care biologics.

In October 2023, MTF Biologics announced that the FDA granted an IDE (Investigational Device Exemption) to initiate a clinical study verifying the efficacy and safety of FlexHD Pliable for breast reconstruction based on implants. This is the first IDE approval for a human acellular dermal matrix for breast reconstruction granted by the FDA.

Future Market Scenario (2024-2031F)

Allografts and xenografts are increasingly being used as skin substitutes beyond just dressings, indicating a shift towards more advanced biologic skin substitutes.

Bioengineered skin substitutes are gaining prominence as an alternative approach to treating large skin defects caused by burns or trauma. These substitutes can be classified based on their chemical composition, scaffold material, and skin components.

Incorporating functional moieties into skin substitutes is a growing trend. For instance, antimicrobials and wound healing agents are being integrated into bioengineered smart skin substitutes. These functionalized substitutes aim to enhance wound healing outcomes and prevent infections.

Key Players Landscape and Outlook

The global wound care biologics market is characterized by a competitive landscape with key players driving innovation and market expansion. These market players are investing in R&D to improve product efficacy, patient comfort, and dosage precision. Partnerships and collaborations between medical device and pharmaceutical companies are being formed with the aim of the development of advanced wound care products that can be integrated with smartphones and applications.

For instance, in May 2023, the Acellular dermal matrix, a natural soft tissue reconstruction solution that AlloSource announced to provide long-term structural support, AlloMend Duo ADM was developed to assist surgeons in reconstructing soft tissue defects. A scaffold for cell repopulation and natural host tissue regeneration is provided by the deep reticular dermal allograft, which blends in with the surrounding tissue.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Wound Care Biologics Market Outlook, 2017-2031F

  • 4.1.Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2.By Product
    • 4.2.1. Biological Skin Substitutes
    • 4.2.2. Topical Agents
  • 4.3.By Wound
    • 4.3.1. Ulcers
    • 4.3.2. Surgical & Traumatic Wounds
    • 4.3.3. Burns
  • 4.4.By End-user
    • 4.4.1. Hospitals & Clinics
    • 4.4.2. Ambulatory Surgical Centers
    • 4.4.3. Burn Care Centers & Wound Clinic
  • 4.5.By Region
    • 4.5.1.North America
    • 4.5.2.Europe
    • 4.5.3.Asia-Pacific
    • 4.5.4.South America
    • 4.5.5.Middle East and Africa
  • 4.6.By Company Market Share (%), 2023

5.Global Wound Care Biologics Market Outlook, By Region, 2017-2031F

  • 5.1.North America*
    • 5.1.1.Market Size & Forecast
      • 5.1.1.1.By Value
      • 5.1.1.2.By Volume
    • 5.1.2.By Product
      • 5.1.2.1.Biological Skin Substitutes
      • 5.1.2.2.Topical Agents
    • 5.1.3.By Wound
      • 5.1.3.1.Ulcers
      • 5.1.3.2.Surgical & Traumatic Wounds
      • 5.1.3.3.Burns
    • 5.1.4.By End-user
      • 5.1.4.1.Hospitals & Clinics
      • 5.1.4.2.Ambulatory Surgical Centers
      • 5.1.4.3.Burn Care Centers & Wound Clinic
    • 5.1.5.United States*
      • 5.1.5.1.Market Size & Forecast
      • 5.1.5.1.1.By Value
      • 5.1.5.1.2.By Volume
      • 5.1.5.2.By Product
      • 5.1.5.2.1.Biological Skin Substitutes
      • 5.1.5.2.2.Topical Agents
      • 5.1.5.3.By Wound
      • 5.1.5.3.1.Ulcers
      • 5.1.5.3.2.Surgical & Traumatic Wounds
      • 5.1.5.3.3.Burns
      • 5.1.5.4.By End-user
      • 5.1.5.4.1.Hospitals & Clinics
      • 5.1.5.4.2.Ambulatory Surgical Centers
      • 5.1.5.4.3.Burn Care Centers & Wound Clinic
    • 5.1.6.Canada
    • 5.1.7.Mexico

All segments will be provided for all regions and countries covered

  • 5.2.Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3.Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4.South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5.Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. U.A.E.
    • 5.5.3. South Africa

6.Market Mapping, 2023

  • 6.1.By Product
  • 6.2.By Wound
  • 6.3.By End-user
  • 6.4.By Region

7.Macro Environment and Industry Structure

  • 7.1.Demand Supply Analysis
  • 7.2.Import Export Analysis
  • 7.3.Value Chain Analysis
  • 7.4.PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5.Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8.Market Dynamics

  • 8.1.Growth Drivers
  • 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

  • 9.1.Clinical Trials
  • 9.2.Patent Landscape
  • 9.3.Innovations/Emerging Technologies

10.Key Players Landscape

  • 10.1.Competition Matrix of Top Five Market Leaders
  • 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4.SWOT Analysis (For Five Market Players)
  • 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

  • 13.1.Smith & Nephew Plc
    • 13.1.1.Company Details
    • 13.1.2.Key Management Personnel
    • 13.1.3.Products & Services
    • 13.1.4.Financials (As reported)
    • 13.1.5.Key Market Focus & Geographical Presence
    • 13.1.6.Recent Developments
  • 13.2.Integra LifeSciences Corporation
  • 13.3.Stryker Corporation
  • 13.4.Organogenesis Inc
  • 13.5.MixMedx Inc
  • 13.6.Kerecis Limited
  • 13.7.Molnlycke Healthcare AB
  • 13.8.Lynch Biologics
  • 13.9.Skye Biologics Holdings LLC
  • 13.10.Marine Polymer Technologies Inc

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.Global Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 2.Global Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 3.Global Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 4.Global Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 5.Global Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 6.Global Wound Care Biologics Market Share (%), By Region, 2017-2031F
  • Figure 7.North America Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 8.North America Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 9.North America Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 10.North America Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 11.North America Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 12.North America Wound Care Biologics Market Share (%), By Country, 2017-2031F
  • Figure 13.United States Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 14.United States Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 15.United States Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 16.United States Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 17.United States Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 18.Canada Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 19.Canada Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 20.Canada Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 21.Canada Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 22.Canada Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 23.Mexico Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 24.Mexico Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 25.Mexico Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 26.Mexico Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 27.Mexico Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 28.Europe Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 29.Europe Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 30.Europe Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 31.Europe Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 32.Europe Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 33.Europe Wound Care Biologics Market Share (%), By Country, 2017-2031F
  • Figure 34.Germany Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 35.Germany Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 36.Germany Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 37.Germany Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 38.Germany Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 39.France Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 40.France Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 41.France Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 42.France Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 43.France Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 44.Italy Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 45.Italy Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 46.Italy Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 47.Italy Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 48.Italy Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 49.United Kingdom Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 50.United Kingdom Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 51.United Kingdom Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 52.United Kingdom Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 53.United Kingdom Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 54.Russia Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 55.Russia Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 56.Russia Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 57.Russia Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 58.Russia Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 59.Netherlands Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 60.Netherlands Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 61.Netherlands Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 62.Netherlands Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 63.Netherlands Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 64.Spain Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 65.Spain Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 66.Spain Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 67.Spain Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 68.Spain Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 69.Turkey Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 70.Turkey Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 71.Turkey Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 72.Turkey Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 73.Turkey Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 74.Poland Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 75.Poland Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 76.Poland Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 77.Poland Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 78.Poland Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 79.South America Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 80.South America Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 81.South America Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 82.South America Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 83.South America Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 84.South America Wound Care Biologics Market Share (%), By Country, 2017-2031F
  • Figure 85.Brazil Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 86.Brazil Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 87.Brazil Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 88.Brazil Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 89.Brazil Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 90.Argentina Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 91.Argentina Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 92.Argentina Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 93.Argentina Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 94.Argentina Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 95.Asia-Pacific Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 96.Asia-Pacific Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 97.Asia-Pacific Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 98.Asia-Pacific Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 99.Asia-Pacific Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 100.Asia-Pacific Wound Care Biologics Market Share (%), By Country, 2017-2031F
  • Figure 101.India Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 102.India Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 103.India Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 104.India Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 105.India Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 106.China Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 107.China Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 108.China Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 109.China Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 110.China Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 111.Japan Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 112.Japan Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 113.Japan Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 114.Japan Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 115.Japan Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 116.Australia Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 117.Australia Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 118.Australia Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 119.Australia Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 120.Australia Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 121.Vietnam Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 122.Vietnam Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 123.Vietnam Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 124.Vietnam Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 125.Vietnam Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 126.South Korea Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 127.South Korea Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 128.South Korea Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 129.South Korea Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 130.South Korea Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 131.Indonesia Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 132.Indonesia Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 133.Indonesia Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 134.Indonesia Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 135.Indonesia Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 136.Philippines Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 137.Philippines Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 138.Philippines Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 139.Philippines Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 140.Philippines Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 141.Middle East & Africa Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 142.Middle East & Africa Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 143.Middle East & Africa Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 144.Middle East & Africa Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 145.Middle East & Africa Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 146.Middle East & Africa Wound Care Biologics Market Share (%), By Country, 2017-2031F
  • Figure 147.Saudi Arabia Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 148.Saudi Arabia Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 149.Saudi Arabia Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 150.Saudi Arabia Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 151.Saudi Arabia Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 152.UAE Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 153.UAE Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 154.UAE Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 155.UAE Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 156.UAE Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 157.South Africa Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 158.South Africa Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 159.South Africa Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 160.South Africa Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 161.South Africa Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 162.By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163.By Wound Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023